Literature DB >> 11579440

Role of drug metabolism in drug discovery and development.

G N Kumar1, S Surapaneni.   

Abstract

Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. High metabolic lability usually leads to poor bioavailability and high clearance. Formation of active or toxic metabolites will have an impact on the pharmacological and toxicological outcomes. There is also potential for drug-drug interactions with coadministered drugs due to inhibition and/or induction of drug metabolism pathways. Hence, optimization of the metabolic liability and drug-drug interaction potential of the new chemical entities are some of the most important steps during the drug discovery process. The rate and site(s) of metabolism of new chemical entities by drug metabolizing enzymes are amenable to modulation by appropriate structural changes. Similarly, the potential for drug-drug interactions can also be minimized by appropriate structural modifications to the drug candidate. However, the optimization of the metabolic stability and drug-drug interaction potential during drug discovery stage has been largely by empirical methods and by trial and error. Recently, a lot of effort has been applied to develop predictive methods to aid the optimization process during drug discovery and development. This article reviews the role of drug metabolism in drug discovery and development. Copyright 2001 John Wiley & Sons, Inc. Med Res Rev, 21, No. 5, 397-411, 2001

Mesh:

Substances:

Year:  2001        PMID: 11579440     DOI: 10.1002/med.1016

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  43 in total

1.  Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells.

Authors:  Leslie Tompkins; Caitlin Lynch; Sam Haidar; James Polli; Hongbing Wang
Journal:  Pharm Res       Date:  2010-05-26       Impact factor: 4.200

2.  A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.

Authors:  Jan M Kriegl; Thomas Arnhold; Bernd Beck; Thomas Fox
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

3.  Microbial metabolism studies of cyanthiwigin B and synergetic antibiotic effects.

Authors:  Jiangnan Peng; Noer Kasanah; Charles E Stanley; Jennifer Chadwick; Frank R Fronczek; Mark T Hamann
Journal:  J Nat Prod       Date:  2006-05       Impact factor: 4.050

4.  A simple model predicts UGT-mediated metabolism.

Authors:  Na Le Dang; Tyler B Hughes; Varun Krishnamurthy; S Joshua Swamidass
Journal:  Bioinformatics       Date:  2016-06-20       Impact factor: 6.937

5.  Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.

Authors:  Sravani Adusumalli; Rohitash Jamwal; R Scott Obach; Tim F Ryder; Lorenzo Leggio; Fatemeh Akhlaghi
Journal:  Drug Metab Dispos       Date:  2019-06-10       Impact factor: 3.922

6.  A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.

Authors:  Olga Trubetskoy; Bryan Marks; Thomas Zielinski; Mei-Fei Yueh; Judy Raucy
Journal:  AAPS J       Date:  2005-03-04       Impact factor: 4.009

Review 7.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

Review 8.  Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.

Authors:  Hongbing Wang; Edward L LeCluyse
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction.

Authors:  Haiyan Li; Jin Sun; Xiaowen Fan; Xiaofan Sui; Lan Zhang; Yongjun Wang; Zhonggui He
Journal:  J Comput Aided Mol Des       Date:  2008-06-24       Impact factor: 3.686

10.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.

Authors:  K-C Cheng; Walter A Korfmacher; Ronald E White; F George Njoroge
Journal:  Perspect Medicin Chem       Date:  2007-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.